These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1340 related articles for article (PubMed ID: 31777929)

  • 1. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
    Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
    Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
    J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
    Helwig U; Braegger F; Kostev K; Schmidt C
    Dig Dis; 2020; 38(6):466-473. PubMed ID: 32045927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapies in inflammatory bowel disease.
    Cohen LB; Nanau RM; Delzor F; Neuman MG
    Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
    Holko P; Kawalec P; Pilc A
    Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
    Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic Therapy for Ulcerative Colitis.
    Bhattacharya A; Osterman MT
    Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
    Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
    Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.